Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV.
Alzheimer’s dementia
Blood–brain barrier
Cerebrospinal fluid biomarkers
HIV
Herpes simplex
Varicella zoster
Journal
Journal of neurovirology
ISSN: 1538-2443
Titre abrégé: J Neurovirol
Pays: United States
ID NLM: 9508123
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
31
07
2022
accepted:
27
10
2022
revised:
20
09
2022
medline:
13
4
2023
pubmed:
10
11
2022
entrez:
9
11
2022
Statut:
ppublish
Résumé
Among 128 adult people living with HIV and no neurological conditions confounding the cerebrospinal fluid results, the presence of HSV-1 chronic infection (detected either by serology or PCR), but not of HSV-2 and VZV, independently associated with higher odds of blood-brain barrier impairment, abnormally increased cerebrospinal fluid levels of tau and phosphorylated-181 tau, and decreased concentrations of fragments 1-42 of beta amyloid compared to the seronegative counterpart. These associations were even stronger for seropositive participants with a positive history of at least one symptomatic reactivation of HSV-1.
Identifiants
pubmed: 36352195
doi: 10.1007/s13365-022-01105-z
pii: 10.1007/s13365-022-01105-z
doi:
Substances chimiques
Amyloid beta-Peptides
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100-105Informations de copyright
© 2022. Journal of NeuroVirology, Inc.
Références
Aiello AE, Haan M, Blythe L et al (2006) The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc 54:1046–1054. https://doi.org/10.1111/j.1532-5415.2006.00796.x
doi: 10.1111/j.1532-5415.2006.00796.x
pubmed: 16866674
Alvarez G, Aldudo J, Alonso M et al (2012) Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J Neurosci Res 90:1020–1029. https://doi.org/10.1002/jnr.23003
doi: 10.1002/jnr.23003
pubmed: 22252837
Bourgade K, Le Page A, Bocti C et al (2016) Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture model. J Alzheimers Dis 50:1227–1241. https://doi.org/10.3233/JAD-150652
doi: 10.3233/JAD-150652
pubmed: 26836158
Calcagno A, Celani L, Trunfio M et al (2021) Alzheimer dementia in people living with HIV. Neurol Clin Pract 11:e627–e633. https://doi.org/10.1212/CPJ.0000000000001060
doi: 10.1212/CPJ.0000000000001060
pubmed: 34840876
pmcid: 8610525
Caligaris G, Trunfio M, Ghisetti V et al (2021) Blood-brain barrier impairment in patients living with HIV: predictors and associated biomarkers. Diagnostics (basel) 11:867. https://doi.org/10.3390/diagnostics11050867
doi: 10.3390/diagnostics11050867
pubmed: 34065785
De Chiara G, Piacentini R, Fabiani M et al (2019) Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathog 15:e1007617. https://doi.org/10.1371/journal.ppat.1007617
doi: 10.1371/journal.ppat.1007617
pubmed: 30870531
pmcid: 6417650
Devanand DP, Andrews H, Kreisl WC et al (2020) Antiviral therapy: valacyclovir treatment of Alzheimer’s disease (VALAD) trial: protocol for a randomised, double-blind, placebo-controlled, treatment trial. BMJ Open 10:e032112. https://doi.org/10.1136/bmjopen-2019-032112
doi: 10.1136/bmjopen-2019-032112
pubmed: 32034019
pmcid: 7045215
Fields JA, Swinton MK, Soontornniyomkij B et al (2020) Beta amyloid levels in cerebrospinal fluid of HIV-infected people vary by exposure to antiretroviral therapy. AIDS 34:1001–1007. https://doi.org/10.1097/QAD.0000000000002506
doi: 10.1097/QAD.0000000000002506
pubmed: 32073451
Harris SA, Harris EA (2018) Molecular mechanisms for herpes simplex virus type 1 pathogenesis in Alzheimer’s disease. Front Aging Neurosci 10:48. https://doi.org/10.3389/fnagi.2018.00048
doi: 10.3389/fnagi.2018.00048
pubmed: 29559905
pmcid: 5845560
Hategan A, Masliah E, Nath A (2019) HIV and Alzheimer’s disease: complex interactions of HIV-Tat with amyloid β peptide and Tau protein. J Neurovirol 25:648–660. https://doi.org/10.1007/s13365-019-00736-z
doi: 10.1007/s13365-019-00736-z
pubmed: 31016584
pmcid: 9056081
Itzhaki RF (2021) Overwhelming evidence for a major role for herpes simplex virus type 1 (HSV1) in Alzheimer’s disease (AD); underwhelming evidence against. Vaccines (basel) 9:679. https://doi.org/10.3390/vaccines9060679
doi: 10.3390/vaccines9060679
pubmed: 34205498
Kobayashi N, Nagata T, Shinagawa S et al (2013) Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer’s disease. Biochem Biophys Res Commun 430:907–911. https://doi.org/10.1016/j.bbrc.2012.12.054
doi: 10.1016/j.bbrc.2012.12.054
pubmed: 23261465
Letendre S, Bharti A, Perez-Valero I et al (2018) Higher anti-cytomegalovirus immunoglobulin G concentrations are associated with worse neurocognitive performance during suppressive antiretroviral therapy. Clin Infect Dis 67:770–777. https://doi.org/10.1093/cid/ciy170
doi: 10.1093/cid/ciy170
pubmed: 29506084
pmcid: 6093999
Lopatko Lindman K, Hemmingsson E-S, Weidung B et al (2021) Herpesvirus infections, antiviral treatment, and the risk of dementia-a registry-based cohort study in Sweden. Alzheimers Dement (n y) 7:e12119. https://doi.org/10.1002/trc2.12119
doi: 10.1002/trc2.12119
pubmed: 33614892
Lövheim H, Gilthorpe J, Adolfsson R et al (2015) Reactivated herpes simplex infection increases the risk of Alzheimer’s disease. Alzheimers Dement 11:593–599. https://doi.org/10.1016/j.jalz.2014.04.522
doi: 10.1016/j.jalz.2014.04.522
pubmed: 25043910
Marchi S, Trombetta CM, Gasparini R et al (2017) Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study from 2000 to 2014. J Prev Med Hyg 58:E27–E33
pubmed: 28515628
pmcid: 5432775
Powell-Doherty RD, Abbott ARN, Nelson LA, Bertke AS (2020) Amyloid-β and p-tau anti-threat response to herpes simplex virus 1 infection in primary adult murine hippocampal neurons. J Virol 94:e01874-e1919. https://doi.org/10.1128/JVI.01874-19
doi: 10.1128/JVI.01874-19
pubmed: 32075924
pmcid: 7163132
Protto V, Marcocci ME, Miteva MT et al (2022) Role of HSV-1 in Alzheimer’s disease pathogenesis: a challenge for novel preventive/therapeutic strategies. Curr Opin Pharmacol 63:102200. https://doi.org/10.1016/j.coph.2022.102200
doi: 10.1016/j.coph.2022.102200
pubmed: 35276497
Soontornniyomkij V, Umlauf A, Soontornniyomkij B et al (2018) Association of antiretroviral therapy with brain aging changes among HIV-infected adults. AIDS 32:2005–2015. https://doi.org/10.1097/QAD.0000000000001927
doi: 10.1097/QAD.0000000000001927
pubmed: 29912063
Trunfio M, Atzori C, Pasquero M et al (2022) Patterns of cerebrospinal fluid Alzheimer’s dementia biomarkers in people living with HIV: cross-sectional study on associated factors according to viral control, neurological confounders and neurocognition. Viruses 14:753. https://doi.org/10.3390/v14040753
doi: 10.3390/v14040753
pubmed: 35458483
pmcid: 9031633
Tzeng N-S, Chung C-H, Lin F-H et al (2018) Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—a nationwide, population-based cohort study in Taiwan. Neurotherapeutics 15:417–429. https://doi.org/10.1007/s13311-018-0611-x
doi: 10.1007/s13311-018-0611-x
pubmed: 29488144
pmcid: 5935641
Weidung B, Hemmingsson E-S, Olsson J et al (2022) VALZ-Pilot: high-dose valacyclovir treatment in patients with early-stage Alzheimer’s disease. Alzheimers Dement (n y) 8:e12264. https://doi.org/10.1002/trc2.12264
doi: 10.1002/trc2.12264
pubmed: 35310522
Xu F, Schillinger JA, Sternberg MR et al (2002) Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988–1994. J Infect Dis 185:1019–1024. https://doi.org/10.1086/340041
doi: 10.1086/340041
pubmed: 11930310
Yousuf W, Ibrahim H, Harfouche M et al (2020) Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. BMJ Glob Health 5:e002388. https://doi.org/10.1136/bmjgh-2020-002388
doi: 10.1136/bmjgh-2020-002388
pubmed: 32675066
pmcid: 7369148
Zhang N, Zuo Y, Jiang L et al (2021) Epstein-Barr virus and neurological diseases. Front Mol Biosci 8:816098. https://doi.org/10.3389/fmolb.2021.816098
doi: 10.3389/fmolb.2021.816098
pubmed: 35083281